In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5298-5302

  Sugihara, Kiyoshi ^a   Sugihara, Chika ^a   Matsushita, Yoko ^a   Yamamura, Naotoshi ^a   Uemori, Mitsutoshi ^a   Tokumitsu, Akane ^a   Inoue, Harumi ^a   Kakuta, Masayo ^a   Namba, Eiko ^a   Nasu, Hatsumi ^a   Koga, Tetsufumi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TOMOPENEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; THIGH;

ANIMALS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED ICR; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; THIGH;

EID: 78649665037     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00267-10     Document Type: Article

References (26)

1. Andes, D., and W. A. Craig. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379.
2. Andes, D., and W. A. Craig. 2006. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob. Agents Chemother. 50:1376-1383.
3. Andes, D., S. Kiem, and W. A. Craig. 2003. In vivo pharmacodynamic activity of a new carbapenem, doripenem (DOR), against multiple bacteria in a murine thigh infection model. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-308.
4. Andes, D., M. L. van Ogtrop, J. Peng, and W. A. Craig. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484-3489.
5. Bodmann, K. F. 2005. Current guidelines for the treatment of severe pneumonia and sepsis. Chemotherapy 51:227-233.
6. Clinical and Laboratory Standards Institute. 2006. M7-A7. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
8. Craig, W. A., and D. R. Andes. 2008. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob. Agents Chemother. 52:3492-3496.
9. DeRyke, C. A., D. Maglio, and D. P. Nicolau. 2005. Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalized patient. Expert Opin. Pharmacother. 6:873-889.
10. DeRyke, C. A., M. A. Banevicius, H. W. Fan, and D. P. Nicolau. 2007. Bactericidal activities of meropenem and ertapenem against extended-spectrum- β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob. Agents Chemother. 51:1481-1486.
11. Eguchi, K., K. Kanazawa, Y. Eriguchi, and Y. Ueda. 2009. Pharmacodynamics of SMP-601 (PTZ601) against vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in neutropenic murine thigh infection models. Antimicrob. Agents Chemother. 53:3391-3398.
12. Griffith, D. C., D. Rodriguez, E. Corcoran, and M. N. Dudley. 2008. Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a neutropenic mouse thigh infection model. Antimicrob. Agents Chemother. 52:244-247.
13. Kim, A., M. A. Banevicius, and D. P. Nicolau. 2008. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob. Agents Chemother. 52:2497-2502.
14. Koga, T., N. Masuda, M. Kakuta, E. Namba, C. Sugihara, and T. Fukuoka. 2008. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52:2849-2854.
15. Koga, T., T. Abe, H. Inoue, T. Takenouchi, A. Kitayama, T. Yoshida, N. Masuda, C. Sugihara, M. Kakuta, M. Nakagawa, T. Shibayama, Y. Matsushita, T. Hirota, S. Ohya, Y. Utsui, T. Fukuoka, and S. Kuwahara. 2005. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob. Agents Chemother. 49:3239-3250.
16. Masuda, N., T. Takenouchi, M. Kakuta, C. Ishii, E. Sakagawa, T. Abe, Y. Utsui, S. Ohya, and S. Kuwahara. 2000. R-115685, a novel parenteral carbapenem: mode of action and resistance mechanisms. Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-1231.
17. Morinaga, Y., K. Yanagihara, S. Nakamura, K. Yamamoto, K. Izumikawa, M. Seki, H. Kakeya, Y. Yamamoto, Y. Yamada, S. Kohno, and S. Kamihira. 2008. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model. J. Antimicrob. Chemother. 62:1326-1331.
18. Nicolau, D. P. 2008. Carbapenems: a potent class of antibiotics. Expert Opin. Pharmacother. 9:23-37.
19. Rosenthal, V. D., D. G. Maki, A. Mehta, C. Alvarez-Moreno, H. Leblebicioglu, F. Higuera, L. E. Cuellar, N. Madani, Z. Mitrev, L. Duenas, J. A. Navoa-Ng, H. G. Garcell, L. Raka, R. F. Hidalgo, E. A. Medeiros, S. S. Kanj, S. Abubakar, P. Nercelles, and R. D. Pratesi of the International Nosocomial Infection Control Consortium. 2008. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am. J. Infect. Control 36:627-637.
20. Shibata, K., R. Nagano, T. Hashizume, and H. Morishima. 2000. Therapeutic efficacy of J-111,225, a novel trans-3,5-disubstituted pyrrolidinylthio- 1β-methylcarbapenem, against experimental murine systemic infections. J. Antimicrob. Chemother. 45:379-382.
21. Shibayama, T., Y. Matsushita, T. Hirota, T. Ikeda, and S. Kuwahara. 2006. Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers. Antimicrob. Agents Chemother. 50:4186-4188.
22. Shibayama, T., Y. Matsushita, A. Kurihara, T. Hirota, and T. Ikeda. 2007. Prediction of pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in humans using animal data. Xenobiotica 37:91-102. (Pubitemid 46009559)
23. Sugihara, K., C. Sugihara, Y. Matsushita, N. Yamamura, M. Uemori, A. Tokumitsu, H. Inoue, M. Kakuta, E. Namba, H. Nasu, and T. Koga. 2008. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-027.
24. Sumita, Y., H. Nouda, E. Tada, T. Kohzuki, M. Kato, T. Okuda, and M. Fukasawa. 1992. Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administered to laboratory animals. Chemotherapy 40(Suppl. 1):123-131.
25. Tomozawa, T., C. Sugihara, M. Kakuta, K. Sugihara, and T. Koga. 2010. In vitro postantibiotic effects of tomopenem (CS-023) against Staphylococcus aureus and Pseudomonas aeruginosa. J. Med. Microbiol. 59:438-441.
26. Tsuji, M., Y. Ishii, A. Ohno, S. Miyazaki, and K. Yamaguchi. 1998. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob. Agents Chemother. 42:94-99.